CombiMatrix Selected by ProPath to Provide CMA Testing for Miscarriage Analysis

CombiMatrix (Nasdaq: CBMX ) today announced that it has been selected by ProPath® to provide its chromosomal microarray analysis (CMA) testing for miscarriage analysis for ProPath patients. ProPath, based in Dallas, is a wholly physician-owned provider of pathology services to clinicians, hospitals, reference laboratories and medical facilities nationwide.